Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Laura Gault, MD
AbbVie
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
39 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 84173
Gatineau, Canada
- Site Reference Id/investigator# 84174
Montreal, Canada
- Site Reference Id/investigator# 84177
Peterborough, Canada
- Site Reference Id/investigator# 84175
Toronto, Canada
- Site Reference Id/investigator# 84176
Verdun, Canada
- Site Reference Id/investigator# 84376
Dijon, France
- Site Reference Id/investigator# 84373
Limoges, France
- Site Reference Id/investigator# 84374
Paris, France
- Site Reference Id/investigator# 84377
Paris, France
- Site Reference Id/investigator# 84375
Toulouse, France
- Site Reference Id/investigator# 84382
Berlin, Germany
- Site Reference Id/investigator# 84380
Freiburg im Breisgau, Germany
- Site Reference Id/investigator# 84383
Hüttenberg, Germany
- Site Reference Id/investigator# 84379
Mittweida, Germany
- Site Reference Id/investigator# 84381
Munich, Germany
- Site Reference Id/investigator# 84378
Schwerin, Germany
- Site Reference Id/investigator# 84385
Athens, Greece
- Site Reference Id/investigator# 84388
Athens, Greece
- Site Reference Id/investigator# 84389
Athens, Greece
- Site Reference Id/investigator# 84386
Haidari, Athens, Greece
- Site Reference Id/investigator# 84390
Thessaloniki, Greece
- Site Reference Id/investigator# 84395
Belville, South Africa
- Site Reference Id/investigator# 84391
Cape Town, South Africa
- Site Reference Id/investigator# 84393
George, South Africa
- Site Reference Id/investigator# 84394
Johannesburg, South Africa
- Site Reference Id/investigator# 84392
Rosebank, South Africa
- Site Reference Id/investigator# 84398
Bath, United Kingdom
- Site Reference Id/investigator# 84397
Glasgow, United Kingdom
- Site Reference Id/investigator# 84400
London, United Kingdom
- Site Reference Id/investigator# 84399
Manchester, United Kingdom
- Site Reference Id/investigator# 84185
Long Beach, California, United States
- Site Reference Id/investigator# 84183
San Francisco, California, United States
- Site Reference Id/investigator# 84187
Hamden, Connecticut, United States
- Site Reference Id/investigator# 84178
Delray Beach, Florida, United States
- Site Reference Id/investigator# 84180
Orlando, Florida, United States
- Site Reference Id/investigator# 84186
West Palm Beach, Florida, United States
- Site Reference Id/investigator# 84182
Elk Grove Village, Illinois, United States
- Site Reference Id/investigator# 84181
Staten Island, New York, United States
- Site Reference Id/investigator# 84179
Bennington, Vermont, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2012
- Primary completion
- 28 Feb 2014
- Completion
- 28 Feb 2014
- Last update posted
- 2 Aug 2021
- Registered enrollment
- 343
- Registry id
- NCT01690195
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.